JP7292566B2 - 子宮筋腫を治療し、月経失血を低下させるゴナドトロピン放出ホルモンアンタゴニスト投与計画 - Google Patents
子宮筋腫を治療し、月経失血を低下させるゴナドトロピン放出ホルモンアンタゴニスト投与計画 Download PDFInfo
- Publication number
- JP7292566B2 JP7292566B2 JP2019566909A JP2019566909A JP7292566B2 JP 7292566 B2 JP7292566 B2 JP 7292566B2 JP 2019566909 A JP2019566909 A JP 2019566909A JP 2019566909 A JP2019566909 A JP 2019566909A JP 7292566 B2 JP7292566 B2 JP 7292566B2
- Authority
- JP
- Japan
- Prior art keywords
- weeks
- day
- patient
- days
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000010260 leiomyoma Diseases 0.000 title claims description 90
- 206010046798 Uterine leiomyoma Diseases 0.000 title claims description 89
- 230000002175 menstrual effect Effects 0.000 title description 174
- 210000004369 blood Anatomy 0.000 title description 166
- 239000008280 blood Substances 0.000 title description 166
- 239000002474 gonadorelin antagonist Substances 0.000 title description 144
- 150000001875 compounds Chemical class 0.000 claims description 597
- 239000004381 Choline salt Substances 0.000 claims description 72
- 235000019417 choline salt Nutrition 0.000 claims description 72
- 150000003839 salts Chemical class 0.000 claims description 68
- 239000008194 pharmaceutical composition Substances 0.000 claims description 47
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical group C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims 2
- 238000000034 method Methods 0.000 description 322
- 238000002560 therapeutic procedure Methods 0.000 description 316
- 238000011282 treatment Methods 0.000 description 282
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 252
- 229940053934 norethindrone Drugs 0.000 description 249
- 229960005309 estradiol Drugs 0.000 description 237
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 205
- 229940121381 gonadotrophin releasing hormone (gnrh) antagonists Drugs 0.000 description 165
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 description 154
- 229960001652 norethindrone acetate Drugs 0.000 description 154
- 210000002966 serum Anatomy 0.000 description 153
- 238000001727 in vivo Methods 0.000 description 104
- 230000027758 ovulation cycle Effects 0.000 description 101
- 230000003442 weekly effect Effects 0.000 description 80
- 229940011871 estrogen Drugs 0.000 description 74
- 239000000262 estrogen Substances 0.000 description 74
- 239000000186 progesterone Substances 0.000 description 72
- 229960003387 progesterone Drugs 0.000 description 72
- 239000000583 progesterone congener Substances 0.000 description 71
- 201000000736 Amenorrhea Diseases 0.000 description 66
- 206010001928 Amenorrhoea Diseases 0.000 description 66
- 231100000540 amenorrhea Toxicity 0.000 description 66
- 210000000988 bone and bone Anatomy 0.000 description 62
- 150000003248 quinolines Chemical class 0.000 description 62
- 150000002148 esters Chemical class 0.000 description 59
- 229910052500 inorganic mineral Inorganic materials 0.000 description 56
- 239000011707 mineral Substances 0.000 description 56
- 230000009467 reduction Effects 0.000 description 52
- 230000000694 effects Effects 0.000 description 50
- 239000000203 mixture Substances 0.000 description 50
- 230000002045 lasting effect Effects 0.000 description 47
- 239000002552 dosage form Substances 0.000 description 46
- 229960004616 medroxyprogesterone Drugs 0.000 description 46
- FRQMUZJSZHZSGN-HBNHAYAOSA-N medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 description 46
- 208000032843 Hemorrhage Diseases 0.000 description 45
- 230000000740 bleeding effect Effects 0.000 description 45
- -1 3-[2-fluoro-5-(2 Chemical class 0.000 description 43
- 229940035811 conjugated estrogen Drugs 0.000 description 40
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 description 39
- 229960004845 drospirenone Drugs 0.000 description 39
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 description 39
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 37
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 37
- 230000007423 decrease Effects 0.000 description 37
- 229960002568 ethinylestradiol Drugs 0.000 description 37
- 239000003814 drug Substances 0.000 description 36
- QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 description 32
- 230000001747 exhibiting effect Effects 0.000 description 32
- 229960000417 norgestimate Drugs 0.000 description 32
- KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 description 32
- 210000002700 urine Anatomy 0.000 description 30
- ZAHDXEIQWWLQQL-IHRRRGAJSA-N Deoxypyridinoline Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(O)=C(C[C@H](N)C([O-])=O)C(CC[C@H](N)C(O)=O)=C1 ZAHDXEIQWWLQQL-IHRRRGAJSA-N 0.000 description 25
- 208000007106 menorrhagia Diseases 0.000 description 25
- 229940124597 therapeutic agent Drugs 0.000 description 25
- 239000000843 powder Substances 0.000 description 22
- 239000002775 capsule Substances 0.000 description 21
- 239000006193 liquid solution Substances 0.000 description 21
- 239000003795 chemical substances by application Substances 0.000 description 20
- 239000007897 gelcap Substances 0.000 description 20
- 230000000977 initiatory effect Effects 0.000 description 20
- 239000006194 liquid suspension Substances 0.000 description 19
- 239000000126 substance Substances 0.000 description 19
- 239000003826 tablet Substances 0.000 description 19
- 230000002829 reductive effect Effects 0.000 description 18
- 208000007502 anemia Diseases 0.000 description 17
- 238000012544 monitoring process Methods 0.000 description 17
- 102000009151 Luteinizing Hormone Human genes 0.000 description 16
- 108010073521 Luteinizing Hormone Proteins 0.000 description 16
- 229940040129 luteinizing hormone Drugs 0.000 description 16
- IIVUJUOJERNGQX-UHFFFAOYSA-N pyrimidine-5-carboxylic acid Chemical compound OC(=O)C1=CN=CN=C1 IIVUJUOJERNGQX-UHFFFAOYSA-N 0.000 description 15
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 14
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 14
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 14
- 229940028334 follicle stimulating hormone Drugs 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 230000001225 therapeutic effect Effects 0.000 description 14
- BMUDPLZKKRQECS-UHFFFAOYSA-K 3-[18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoic acid iron(3+) hydroxide Chemical compound [OH-].[Fe+3].[N-]1C2=C(C)C(CCC(O)=O)=C1C=C([N-]1)C(CCC(O)=O)=C(C)C1=CC(C(C)=C1C=C)=NC1=CC(C(C)=C1C=C)=NC1=C2 BMUDPLZKKRQECS-UHFFFAOYSA-K 0.000 description 13
- 238000011156 evaluation Methods 0.000 description 13
- 229940109738 hematin Drugs 0.000 description 13
- 102000001554 Hemoglobins Human genes 0.000 description 12
- 108010054147 Hemoglobins Proteins 0.000 description 12
- 206010037549 Purpura Diseases 0.000 description 12
- 206010034754 petechiae Diseases 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 208000002193 Pain Diseases 0.000 description 11
- 230000003247 decreasing effect Effects 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 11
- 230000002459 sustained effect Effects 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000003446 ligand Substances 0.000 description 9
- 230000016087 ovulation Effects 0.000 description 9
- KQWHKLZRDFJOCN-UHFFFAOYSA-N thieno[3,4-d]pyrimidine Chemical class N1=CN=CC2=CSC=C21 KQWHKLZRDFJOCN-UHFFFAOYSA-N 0.000 description 9
- 238000004319 19F solid-state nuclear magnetic resonance spectroscopy Methods 0.000 description 8
- 208000008035 Back Pain Diseases 0.000 description 8
- 238000005481 NMR spectroscopy Methods 0.000 description 8
- 229940000425 combination drug Drugs 0.000 description 8
- 230000002596 correlated effect Effects 0.000 description 8
- 210000000689 upper leg Anatomy 0.000 description 8
- 208000000450 Pelvic Pain Diseases 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 238000000634 powder X-ray diffraction Methods 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 230000001755 vocal effect Effects 0.000 description 7
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 6
- 241000283073 Equus caballus Species 0.000 description 6
- 229930182833 estradiol Natural products 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 239000000090 biomarker Substances 0.000 description 5
- 208000034158 bleeding Diseases 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 238000004922 13C solid-state nuclear magnetic resonance spectroscopy Methods 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 108010050808 Procollagen Proteins 0.000 description 4
- 238000009739 binding Methods 0.000 description 4
- 230000002860 competitive effect Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 3
- 208000006386 Bone Resorption Diseases 0.000 description 3
- 102000012422 Collagen Type I Human genes 0.000 description 3
- 108010022452 Collagen Type I Proteins 0.000 description 3
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 206010030247 Oestrogen deficiency Diseases 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 230000024279 bone resorption Effects 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 229960003575 estradiol acetate Drugs 0.000 description 3
- 229960003399 estrone Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229940096452 norethindrone 0.5 mg Drugs 0.000 description 3
- 230000001817 pituitary effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000011477 surgical intervention Methods 0.000 description 3
- 208000010579 uterine corpus leiomyoma Diseases 0.000 description 3
- 201000007954 uterine fibroid Diseases 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 2
- 102000006771 Gonadotropins Human genes 0.000 description 2
- 108010086677 Gonadotropins Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241001181114 Neta Species 0.000 description 2
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000002820 assay format Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 2
- 239000002622 gonadotropin Substances 0.000 description 2
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 2
- 229940094892 gonadotropins Drugs 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000009802 hysterectomy Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 238000000670 ligand binding assay Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000004914 menses Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 102000003998 progesterone receptors Human genes 0.000 description 2
- 108090000468 progesterone receptors Proteins 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- JKKFKPJIXZFSSB-UHFFFAOYSA-N 1,3,5(10)-estratrien-17-one 3-sulfate Natural products OS(=O)(=O)OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 JKKFKPJIXZFSSB-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 101000996727 Homo sapiens Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
- 108010021290 LHRH Receptors Proteins 0.000 description 1
- 102000008238 LHRH Receptors Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 1
- 229960005471 androstenedione Drugs 0.000 description 1
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 1
- 210000004198 anterior pituitary gland Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 210000004252 chorionic villi Anatomy 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000037011 constitutive activity Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 229960001348 estriol Drugs 0.000 description 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 210000004996 female reproductive system Anatomy 0.000 description 1
- 210000005002 female reproductive tract Anatomy 0.000 description 1
- 229910001448 ferrous ion Inorganic materials 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 238000000198 fluorescence anisotropy Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- OKDQKPLMQBXTNH-UHFFFAOYSA-N n,n-dimethyl-2h-pyridin-1-amine Chemical compound CN(C)N1CC=CC=C1 OKDQKPLMQBXTNH-UHFFFAOYSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000000624 ovulatory effect Effects 0.000 description 1
- 210000001819 pancreatic juice Anatomy 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 210000005059 placental tissue Anatomy 0.000 description 1
- 238000001907 polarising light microscopy Methods 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003653 radioligand binding assay Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023043718A JP7485815B2 (ja) | 2017-06-05 | 2023-03-20 | 子宮筋腫を治療し、月経失血を低下させるゴナドトロピン放出ホルモンアンタゴニスト投与計画 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762515232P | 2017-06-05 | 2017-06-05 | |
| US62/515,232 | 2017-06-05 | ||
| PCT/EP2018/064767 WO2018224497A1 (en) | 2017-06-05 | 2018-06-05 | Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023043718A Division JP7485815B2 (ja) | 2017-06-05 | 2023-03-20 | 子宮筋腫を治療し、月経失血を低下させるゴナドトロピン放出ホルモンアンタゴニスト投与計画 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020522525A JP2020522525A (ja) | 2020-07-30 |
| JP2020522525A5 JP2020522525A5 (cg-RX-API-DMAC7.html) | 2021-07-26 |
| JP7292566B2 true JP7292566B2 (ja) | 2023-06-19 |
Family
ID=62636157
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019566909A Active JP7292566B2 (ja) | 2017-06-05 | 2018-06-05 | 子宮筋腫を治療し、月経失血を低下させるゴナドトロピン放出ホルモンアンタゴニスト投与計画 |
| JP2023043718A Active JP7485815B2 (ja) | 2017-06-05 | 2023-03-20 | 子宮筋腫を治療し、月経失血を低下させるゴナドトロピン放出ホルモンアンタゴニスト投与計画 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023043718A Active JP7485815B2 (ja) | 2017-06-05 | 2023-03-20 | 子宮筋腫を治療し、月経失血を低下させるゴナドトロピン放出ホルモンアンタゴニスト投与計画 |
Country Status (18)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3384930A1 (en) | 2013-03-15 | 2018-10-10 | AbbVie Inc. | Compositions for use in treating heavy menstrual bleeding |
| MX2019014482A (es) | 2017-06-05 | 2020-08-17 | ObsEva SA | Régimenes de dosificación de antagonistas de hormona liberadora de gonadotropina para tratar miomas uterinos y reducir la menstruación. |
| KR20250117836A (ko) | 2017-06-05 | 2025-08-05 | 깃세이 야쿠힌 고교 가부시키가이샤 | 자궁내막증의 치료를 위한 고나도트로핀 방출 호르몬 길항제 투약 요법 |
| IL278082B2 (en) | 2018-04-19 | 2025-03-01 | Abbvie Inc | Methods of treating heavy menstrual bleeding |
| CA3107597A1 (en) * | 2018-08-01 | 2020-02-06 | Abbvie Inc. | Dosing regimens for elagolix |
| EP3873465B1 (en) | 2018-10-29 | 2025-01-15 | Kissei Pharmaceutical Co., Ltd. | Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis |
| EP3876943A2 (en) * | 2018-11-07 | 2021-09-15 | ObsEva S.A. | Compositions and methods for the treatment of estrogen-dependent disorders |
| US20220305017A1 (en) * | 2019-08-08 | 2022-09-29 | ObsEva S.A. | Compositions and methods for the treatment of estrogen-dependent disorders |
| CN114364384A (zh) * | 2019-08-08 | 2022-04-15 | 奥布赛瓦股份公司 | 用于治疗雌激素依赖性病症的GnRH拮抗剂 |
| KR20210155350A (ko) | 2020-06-15 | 2021-12-22 | 한상왕 | 녹차 추출물 및 비타민 d3를 유효성분으로 포함하는 자궁근종 개선용 조성물 |
| CN115232144B (zh) * | 2021-04-22 | 2024-04-02 | 长春金赛药业有限责任公司 | 含氮稠环类衍生物、药物组合物及其制备方法和应用 |
| KR102738115B1 (ko) | 2024-03-25 | 2024-12-05 | 한상왕 | 자궁근종 예방, 개선 또는 치료용 약학 조성물 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003525249A (ja) | 2000-02-28 | 2003-08-26 | プラエシス ファーマシューティカルズ インコーポレーテッド | ＧｎＲＨアンタゴニストを用いてＦＳＨ関連状態を治療する方法 |
| WO2011099507A1 (ja) | 2010-02-10 | 2011-08-18 | キッセイ薬品工業株式会社 | 縮合複素環誘導体の塩及びその結晶 |
| JP2016513708A (ja) | 2013-03-15 | 2016-05-16 | アッヴィ・インコーポレイテッド | 月経出血過多および子宮類線維腫の処置に使用するための組成物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0617436B8 (pt) | 2005-10-19 | 2021-05-25 | Kissei Pharmaceutical | derivado heterocíclico fundido, composição farmacêutica compreendendo o mesmo e usos do dito derivado na prevenção ou tratamento de doença dependente de hormônio sexual e na regulação da reprodução, contracepção ou indução de ovulação |
| WO2014042176A1 (ja) | 2012-09-14 | 2014-03-20 | キッセイ薬品工業株式会社 | 縮合複素環誘導体の製造方法およびその製造中間体 |
| CA3025760A1 (en) | 2016-08-08 | 2018-02-15 | Kissei Pharmaceutical Co., Ltd. | Usage and dosage of therapeutic agents for endometriosis |
| DK3518933T4 (da) | 2016-09-30 | 2025-04-22 | Takeda Pharmaceuticals Co | Fremgangsmåder til behandling af uterusfibromer og endometriose |
| MX2019014482A (es) | 2017-06-05 | 2020-08-17 | ObsEva SA | Régimenes de dosificación de antagonistas de hormona liberadora de gonadotropina para tratar miomas uterinos y reducir la menstruación. |
| KR20250117836A (ko) | 2017-06-05 | 2025-08-05 | 깃세이 야쿠힌 고교 가부시키가이샤 | 자궁내막증의 치료를 위한 고나도트로핀 방출 호르몬 길항제 투약 요법 |
| EP3876943A2 (en) | 2018-11-07 | 2021-09-15 | ObsEva S.A. | Compositions and methods for the treatment of estrogen-dependent disorders |
-
2018
- 2018-06-05 MX MX2019014482A patent/MX2019014482A/es unknown
- 2018-06-05 JP JP2019566909A patent/JP7292566B2/ja active Active
- 2018-06-05 US US16/619,702 patent/US11759464B2/en active Active
- 2018-06-05 WO PCT/EP2018/064767 patent/WO2018224497A1/en not_active Ceased
- 2018-06-05 KR KR1020197038980A patent/KR102884301B1/ko active Active
- 2018-06-05 CN CN201880050807.2A patent/CN110996957A/zh active Pending
- 2018-06-05 ES ES18731976T patent/ES3018358T3/es active Active
- 2018-06-05 HR HRP20250390TT patent/HRP20250390T1/hr unknown
- 2018-06-05 SG SG11201911599XA patent/SG11201911599XA/en unknown
- 2018-06-05 PT PT187319769T patent/PT3634419T/pt unknown
- 2018-06-05 DK DK18731976.9T patent/DK3634419T3/da active
- 2018-06-05 HU HUE18731976A patent/HUE070907T2/hu unknown
- 2018-06-05 FI FIEP18731976.9T patent/FI3634419T3/fi active
- 2018-06-05 MX MX2023013582A patent/MX2023013582A/es unknown
- 2018-06-05 CA CA3066188A patent/CA3066188A1/en active Pending
- 2018-06-05 AU AU2018280741A patent/AU2018280741B2/en active Active
- 2018-06-05 EA EA201992812A patent/EA201992812A1/ru unknown
- 2018-06-05 PL PL18731976.9T patent/PL3634419T3/pl unknown
- 2018-06-05 EP EP24221894.9A patent/EP4509173A3/en active Pending
- 2018-06-05 EP EP18731976.9A patent/EP3634419B1/en active Active
-
2023
- 2023-03-20 JP JP2023043718A patent/JP7485815B2/ja active Active
- 2023-09-11 US US18/244,773 patent/US20240000785A1/en active Pending
-
2024
- 2024-03-14 AU AU2024201694A patent/AU2024201694A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003525249A (ja) | 2000-02-28 | 2003-08-26 | プラエシス ファーマシューティカルズ インコーポレーテッド | ＧｎＲＨアンタゴニストを用いてＦＳＨ関連状態を治療する方法 |
| WO2011099507A1 (ja) | 2010-02-10 | 2011-08-18 | キッセイ薬品工業株式会社 | 縮合複素環誘導体の塩及びその結晶 |
| JP2016513708A (ja) | 2013-03-15 | 2016-05-16 | アッヴィ・インコーポレイテッド | 月経出血過多および子宮類線維腫の処置に使用するための組成物 |
Non-Patent Citations (2)
| Title |
|---|
| ANNUAL REPORT 2016，OBSEVA OBSTETRICS & BEYOND，2017年04月21日，Pages 1-48，http://obseva.across.health/wp-content/uploads/2019/07/ObsEva_AR_2016.pdf |
| Fertility and Sterility，2017年06月01日，Vol. 108, No. 1，Pages 152-160 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3634419B1 (en) | 2025-01-29 |
| KR102884301B1 (ko) | 2025-11-11 |
| EP3634419A1 (en) | 2020-04-15 |
| PL3634419T3 (pl) | 2025-06-09 |
| HUE070907T2 (hu) | 2025-07-28 |
| DK3634419T3 (da) | 2025-03-31 |
| US20240000785A1 (en) | 2024-01-04 |
| KR20200024797A (ko) | 2020-03-09 |
| CA3066188A1 (en) | 2018-12-13 |
| ES3018358T3 (es) | 2025-05-16 |
| MX2023013582A (es) | 2024-04-16 |
| US11759464B2 (en) | 2023-09-19 |
| MX2019014482A (es) | 2020-08-17 |
| JP7485815B2 (ja) | 2024-05-16 |
| PT3634419T (pt) | 2025-04-04 |
| JP2023078315A (ja) | 2023-06-06 |
| AU2018280741A1 (en) | 2020-01-30 |
| US20200179390A1 (en) | 2020-06-11 |
| AU2024201694A1 (en) | 2024-04-04 |
| EP4509173A2 (en) | 2025-02-19 |
| FI3634419T3 (fi) | 2025-05-02 |
| EP4509173A3 (en) | 2025-06-04 |
| SG11201911599XA (en) | 2020-01-30 |
| HRP20250390T1 (hr) | 2025-05-23 |
| JP2020522525A (ja) | 2020-07-30 |
| CN110996957A (zh) | 2020-04-10 |
| AU2018280741B2 (en) | 2023-12-21 |
| WO2018224497A1 (en) | 2018-12-13 |
| EA201992812A1 (ru) | 2020-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7292566B2 (ja) | 子宮筋腫を治療し、月経失血を低下させるゴナドトロピン放出ホルモンアンタゴニスト投与計画 | |
| US20240293414A1 (en) | Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis | |
| WO2020094698A2 (en) | Compositions and methods for the treatment of estrogen-dependent disorders | |
| WO2021023877A2 (en) | Compositions and methods for the treatment of estrogen-dependent disorders | |
| EP3873465B1 (en) | Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis | |
| HK40116843A (en) | Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss | |
| EA049129B1 (ru) | Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения миомы матки и уменьшения менструальной кровопотери | |
| HK40027583A (en) | Dosing regimen comprising a gonadotropin-releasing hormone antagonist for treating uterine fibroids and reducing menstrual blood loss | |
| HK40027583B (en) | Dosing regimen comprising a gonadotropin-releasing hormone antagonist for treating uterine fibroids and reducing menstrual blood loss | |
| HK40059353B (en) | Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis | |
| HK40059353A (en) | Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210601 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210601 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220318 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220405 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220613 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20220929 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221005 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230221 |
|
| RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7421 Effective date: 20230224 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230320 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7292566 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |